Sequential treatment of Paget's disease with human calcitonin and dichloromethylene diphosphonate (Cl2MDP)

Metab Bone Dis Relat Res. 1984;5(6):265-7. doi: 10.1016/0221-8747(84)90012-2.

Abstract

Dichloromethylene diphosphonate (Cl2MDP), a powerful inhibitor of bone resorption, was given (daily dose: 500 mg i.v. for 2 months and then 1600 mg p.o.) to five patients with Paget's disease after 8 months treatment with 50-100 MRC u/day of human calcitonin (CT). During treatment with CT plasma alkaline phosphatase (ALP) and urinary hydroxyproline (HOP) levels fell to about 60% of pretreatment values within the first 2 months in all the patients. Cl2MDP therapy resulted in a further drop of urinary HOP to 20% of baseline values, while serum ALP rose impressively during the first 2 weeks of therapy and then slowly fell to 25% of baseline values. We conclude that Cl2MDP can induce a further biochemical response after the so-called plateau phenomenon to CT and that it may represent the therapy of choice for severe Paget's disease.

MeSH terms

  • Aged
  • Alkaline Phosphatase / blood
  • Calcitonin / administration & dosage
  • Calcitonin / therapeutic use*
  • Clodronic Acid / administration & dosage
  • Clodronic Acid / therapeutic use*
  • Diphosphonates / therapeutic use*
  • Female
  • Humans
  • Hydroxyproline / urine
  • Kinetics
  • Male
  • Middle Aged
  • Osteitis Deformans / drug therapy*
  • Osteitis Deformans / metabolism

Substances

  • Diphosphonates
  • Clodronic Acid
  • Calcitonin
  • Alkaline Phosphatase
  • Hydroxyproline